(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 5.25% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.85%.
Gilead Sciences's revenue in 2026 is $29,736,000,000.On average, 34 Wall Street analysts forecast GILD's revenue for 2026 to be $38,533,362,609,464, with the lowest GILD revenue forecast at $36,571,682,208,544, and the highest GILD revenue forecast at $40,440,413,935,928. On average, 33 Wall Street analysts forecast GILD's revenue for 2027 to be $40,810,401,758,380, with the lowest GILD revenue forecast at $37,788,420,685,064, and the highest GILD revenue forecast at $44,055,865,409,016.
In 2028, GILD is forecast to generate $43,035,294,972,588 in revenue, with the lowest revenue forecast at $39,188,911,502,936 and the highest revenue forecast at $48,706,786,157,020.